The addition of veliparib to a highly active platinum doublet, with continuation as monotherapy if the doublet were discontinued, resulted in significant and durable improvement in progression-free survival in patients with germline BRCA mutation-associated advanced breast cancer. These data indicate the utility of combining platinum and PARP inhibitors in this patient population.
PURPOSE To report the long-term results of external-beam accelerated partial-breast irradiation (APBI) intensity-modulated radiation therapy (IMRT) Florence phase III trial comparing whole-breast irradiation (WBI) to APBI in early-stage breast cancer. PATIENTS AND METHODS The primary end point was to determine the 5-year difference in ipsilateral breast tumor recurrence (IBTR) between 30 Gy in 5…
Frontline trastuzumab plus lapatinib and an aromatase inhibitor demonstrated superior progression-free survival compared with the trastuzumab/aromatase inhibitor alone as treatment of patients with HER2-positive, HR-positive metastatic breast cancer.
Interview with Reshma L. Mahtani DO
Written by Lillie D Shockney RN, BS, MAS, ONN-CG
A Novel Testing & Prevention Model
Click on the article title to read more.
The management of human epidermal growth factor receptor (HER2)–positive breast cancer (BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and Drug Administration appr…
Montserrat Garcia-Closas and colleagues report findings from a new genome-wide association study (GWAS) for breast cancer identifying 32 novel susceptibility loci. Importantly, this study reveals genetic risk for breast cancer subtypes and expands the potential for the development of subtype-specific polygenic risk scores.